Amicus inks gene therapy manufacturing deal with Catalent

US biotech Amicus Therapeutics (Nasdaq: FOLD) has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics (NYSE: CTLT).

The deal supports Amicus’ clinical and commercial supply needs for its Pompe and other lysosomal disease gene therapy programs that are currently in development in collaboration with the University of Pennsylvania, which helpfully has worked with Paragon in the past.

John Crowley, chairman and chief executive of Amicus, said: “As we continue to articulate our near- and long-term Amicus gene therapy manufacturing strategy, our collaboration with Paragon is a significant next step in securing clinical scale-up and supply for our Pompe gene therapy, as well as our other active preclinical programs.